Zentalis Pharmaceuticals Announces Incentive Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 3, 2024 (GLOBE NEWSWIRE) — Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapies that target fundamental biological pathways of cancer, today announced that on September 3, 2024, the Compensation Committee of the Board of Directors of Zentalis granted non-qualified stock options to purchase an aggregate of 16,000 shares of the Company’s common stock to 2 newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an incentive for each of such individuals joining Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2022 Inducement Plan will be used solely for the grant of stock options to individuals who were not previously employees of Zentalis, or after a period of bona fide inactivity, as an incentive material to each such individual’s employment with Zentalis, in accordance with Nasdaq Listing Rule 5635(c)(4).